Patent application number | Description | Published |
20090291463 | IMPLEMENTATION OF MICROFLUIDIC COMPONENTS, INCLUDING MOLECULAR FRACTIONATION DEVICES, IN A MICROFLUIDIC SYSTEM - A system and method for integrating microfluidic components in a microfluidic system enables the microfluidic system to perform a selected microfluidic function. A capping module includes a microfluidic element for performing a microfluidic function. The capping module is stacked on a microfluidic substrate having microfluidic plumbing to incorporate the microfluidic function into the system. The microfluidic element may comprise a matrix having an affinity for selected molecules in a sample. The matrix binds, reacts with and/or retains the selected molecules without affecting other molecules in the sample. | 11-26-2009 |
20120009619 | UNITARY CARTRIDGE FOR PARTICLE PROCESSING - A single disposable cartridge for performing a process on a particle, such as particle sorting, encapsulates all fluid contact surfaces in the cartridge for use with microfluidic particle processing technology. The cartridge interfaces with an operating system for effecting particle processing. The encapsulation of the fluid contact surfaces insures, improves or promotes operator isolation and/or product isolation. The cartridge may employ any suitable technique for processing particles. | 01-12-2012 |
20140170673 | UNITARY CARTRIDGE FOR PARTICLE PROCESSING - A single disposable cartridge for performing a process on a particle, such as particle sorting, encapsulates all fluid contact surfaces in the cartridge for use with microfluidic particle processing technology. The cartridge interfaces with an operating system for effecting particle processing. The encapsulation of the fluid contact surfaces insures, improves or promotes operator isolation and/or product isolation. The cartridge may employ any suitable technique for processing particles. | 06-19-2014 |
Patent application number | Description | Published |
20100151003 | EGFR BINDING PEPTIDES AND USES THEREOF - Short oligopeptides are provided which are capable of binding to the epidermal growth factor receptor on the surface of human tumor cells. Methods for using the peptides as targeting moieties in more complex compositions, such as conjugates of cytoxins, and/or structures, such as liposomal structures, for the purposes of drug delivery are also provided. | 06-17-2010 |
20140093523 | Anti-Integrin Immunoconjugates, Methods and Uses - The invention relates to conjugates of anti-integrin specific antibodies with cytotoxic compounds, the synthesis, selection, and use of such conjugates for use in cancer therapy or other diseases mediated by cell proliferation, cell migration, or inflammation and which pathology involves angiogenesis or neovascularization of new tissue. In addition the invention relates to combination therapy of such diseases wherein the treatment comprises use of said conjugates in combination with one or more other treatment modalities including but not limited to: chemotherapy, surgery or radiation therapy. The preferred conjugates contain maytansinoid compounds linked to the antibody by a disulfide linkage, and preferred chemotherapeutic agents are doxorubicin, a taxane, a camptothecin, a podophyllotoxin, a nucleoside analog, or a pyrimidine analog. | 04-03-2014 |
20140141013 | ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES - The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices. | 05-22-2014 |
Patent application number | Description | Published |
20080312172 | Anti-IL-6 Antibodies, Compositions, Methods and Uses - The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices. | 12-18-2008 |
20090191117 | Anti-Integrin Antibodies, Compositions, Methods and Uses - The present invention relates to at least one novel anti-alpha-V subunit antibodies, including isolated nucleic acids that encode at least one anti-alpha-V subunit antibody, alpha-V subunit, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices. | 07-30-2009 |
20090217392 | ANTI- INTEGRIN ANTIBODIES, COMPOSITIONS, METHODS AND USES - The present invention relates to at least one novel anti-alpha-V subunit antibodies, including isolated nucleic acids that encode at least one anti-alpha-V subunit antibody, alpha-V subunit, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices. | 08-27-2009 |
20090291084 | ANTI- IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES - The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices. | 11-26-2009 |
20110218329 | ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES - The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices. | 09-08-2011 |
20120058128 | ANTI- INTEGRIN ANTIBODIES, COMPOSITIONS, METHODS AND USES - The present invention relates to at least one novel anti-alpha-V subunit antibodies, including isolated nucleic acids that encode at least one anti-alpha-V subunit antibody, alpha-V subunit, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices. | 03-08-2012 |
20120096569 | ANTI-IL-6 ANTIBODIES,COMPOSITIONS, METHODS AND USES - The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices. | 04-19-2012 |
Patent application number | Description | Published |
20100273442 | JAMMER DETECTION BASED ADAPTIVE PLL BANDWIDTH ADJUSTMENT IN FM RECEIVER - A frequency synthesizer within an FM receiver employs a Phase-Locked Loop (PLL) to generate a Local Oscillator (LO) signal. The LO signal is supplied to a mixer. The FM receiver also includes jammer detection functionality. If no jammer is detected, then the loop bandwidth of the PLL is set to have a relatively high value, thereby favoring suppression of in-band residual FM. If a jammer is detected, then the loop bandwidth of the PLL is set to have a relatively low value, thereby favoring suppression of out-of-band SSB phase noise. By adaptively changing loop bandwidth depending on whether a jammer is detected, performance requirements on sub-circuits within the PLL can be relaxed while still satisfying in-band residual FM and out-of-band SSB phase noise requirements. By allowing the VCO of the PLL to generate more phase noise due to the adaptive changing of loop bandwidth, VCO power consumption can be reduced. | 10-28-2010 |
20100330941 | FM TRANSMITTER WITH A DELTA-SIGMA MODULATOR AND A PHASE-LOCKED LOOP - A frequency modulation (FM) transmitter implemented with a delta-sigma modulator and a phase-locked loop (PLL) is described. The delta-sigma modulator receives a modulating signal (e.g., an FM stereo multiplex (MPX) signal) and provides a modulator output signal. The PLL performs frequency modulation based on the modulator output signal and provides an FM signal. The FM transmitter may further include a gain/phase compensation unit and a scaling unit. The compensation unit may compensate the modulating signal for the closed-loop response of the PLL. The scaling unit may scale the amplitude of the modulating signal based on a gain to obtain a target frequency deviation for the FM signal. The PLL may operate in a transmit mode or a receive mode, may perform frequency modulation in the transmit mode, and may provide a local oscillator (LO) signal at a fixed frequency in the receive mode. | 12-30-2010 |
20110009161 | USING LO SHIFTING TO PREVENT A LOCAL TRANSCEIVER FROM INTERFERING WITH AN FM RADIO - A cellular telephone includes cellular telephone circuitry and an FM receiver. An FM signal being received is downconverted by a mixer. The downconverted signal is processed to generate an FM signal that is supplied to a digital IF filter. If a blocker emitted by the cellular telephone circuitry would interfere with receiving of the FM signal due to interaction of an LO harmonic with the blocker if a conventional LO frequency were used, then a different LO frequency is used. Subsequent processing of the downconverted FM signal (for example, by a digital complex conjugate selector and an IF rotator) results in the signal supplied to the digital IF filter having the same center frequency as the digital IF filter despite the use of the different LO frequency. In some embodiments, the LO is shifted by different amounts depending on cellular telephone mode and on the FM signal. | 01-13-2011 |